ArticleResearch and practice in thrombosis and haemostasis2026
Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Emicizumab provides effective prophylaxis for hemophilia A (HA), but evidence for preterm and very low-birth-weight infants remains limited. Key Clinical Question: Can emicizumab be safely initiated shortly after birth in a preterm, low-birth-weight infant with severe HA? Clinical Approach: We report a male infant born at 30 + 4 weeks of gestation to a known carrier of severe HA. Because of the high risk of intracranial hemorrhage, the case was reviewed by a multidisciplinary team with shared decision-making. After confirming severe HA and excluding intracranial hemorrhage on cranial ultrasonography, emicizumab prophylaxis was started at 26 hours of life, at a weight of 1.48 kg. Monitoring included emicizumab levels, thrombin generation, and inhibitor testing. The infant completed the loading phase and transitioned to maintenance dosing without bleeding, thrombosis, or adverse events. Conclusion: This case supports the feasibility and early safety of initiating emicizumab in preterm, low-birth-weight infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.